☆ 4.7 Article

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis

David T. Rubin et al.

Summary: The study analyzed post-marketing surveillance case safety reports for tofacitinib in patients with ulcerative colitis, showing that serious adverse events mainly included infections, gastrointestinal issues, and vascular disorders. Most reported adverse events were non-serious.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment

William J. Sandborn et al.

Summary: Tofacitinib demonstrated consistent safety over up to 7.0 years, with data up to Month 36 supporting long-term efficacy in the treatment of ulcerative colitis patients.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Short-term effectiveness and safety of tofacitinib in ulcerative colitis-real world data from tertiary medical centers in Israel

Irit Avni-Biron et al.

Summary: Tofacitinib showed effectiveness and safety in treating moderate to severe ulcerative colitis in Israeli patients, achieving corticosteroid-free remission in about 20% of patients with extensive biologics experience. Despite some patients continuing to use tofacitinib at 26 weeks, it was well tolerated and safe. Earlier use of tofacitinib in the treatment algorithm may lead to improved outcomes.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

Tim Raine et al.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment

Antonino Spinelli et al.

Summary: This article is the second in a series of European Crohn's and Colitis Organisation [ECCO] articles on the management of adult patients with ulcerative colitis [UC]. It provides information on the medical treatment of acute severe ulcerative colitis [ASUC] and the surgical management of medically refractory UC patients.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open

Remo Panaccione et al.

Summary: This analysis evaluated the persistence of tofacitinib treatment in patients with UC. The results showed that a high proportion of patients continued to use tofacitinib for an average of 4.0 to 5.6 years in the OCTAVE Open study.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Review Immunology

Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review

Yuanzhuo Wang et al.

Summary: Extraintestinal manifestations (EIMs) are common in patients with inflammatory bowel disease (IBD) and managing these manifestations is difficult. Recent research has found that tofacitinib (TOF) may be a promising option for treating EIMs. TOF may benefit EIMs in ulcerative colitis, and higher doses and longer treatment times may increase its effectiveness. However, more specific research and large prospective studies are needed.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis

Parakkal Deepak et al.

Summary: In a real-world study of UC patients given tofacitinib, adverse events occurred in 15.7% of patients, most of which were infections. Serious adverse events occurred at a rate of 10.0%, with HZ infection and VTE primarily occurring in patients receiving 10 mg tofacitinib twice per day.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry

Maria Chaparro et al.

Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis

Tessa Straatmijer et al.

Summary: In this study, the combination of steroid-free clinical remission and endoscopic improvement with tofacitinib was found in 39% of patients with refractory UC.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

David T. Rubin et al.

Summary: The presence of EIMs did not impact the efficacy of tofacitinib 10mg BID for induction or maintenance of UC. The most common active EIM was peripheral arthritis, with many patients reporting improvement or no change from baseline with tofacitinib treatment in OCTAVE Induction 1 and 2, and OCTAVE Sustain.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis

Laura A. Lucaciu et al.

Summary: This study summarized observational data on the effectiveness and safety of tofacitinib in moderate to severe ulcerative colitis patients, indicating favorable induction and maintenance of clinical response and remission, but with a considerable proportion of patients experiencing adverse events and discontinuing the treatment.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis

Hiromichi Shimizu et al.

INTESTINAL RESEARCH (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

Bruce E. Sands et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

Loriane Lair-Mehiri et al.

DIGESTIVE AND LIVER DISEASE (2020)

Add to Collection

Review Gastroenterology & Hepatology

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

Javier P. Gisbert et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

Vince B. C. Biemans et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience

Sailish Honap et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Article Medicine, General & Internal

Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study

Peter Hoffmann et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Real-World Experience with Tofacitinib in IBD at a Tertiary Center

Roni Weisshof et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

Add to Collection

Review Gastroenterology & Hepatology

Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis

Fabio Salvatore Macaluso et al.

INFLAMMATORY BOWEL DISEASES (2019)

Add to Collection

Article Gastroenterology & Hepatology

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Maria Chaparro et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

Carlos Taxonera et al.

DIGESTIVE DISEASES AND SCIENCES (2017)

Add to Collection

Article Medicine, General & Internal

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Gastroenterology & Hepatology

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

Lior Katz et al.

INFLAMMATORY BOWEL DISEASES (2012)

Add to Collection

Article Gastroenterology & Hepatology

Long-term durability of response to adalimumab in Crohn's disease

M. Chaparro et al.

INFLAMMATORY BOWEL DISEASES (2012)

Add to Collection

Article Medicine, General & Internal

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Gastroenterology & Hepatology

Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response

Maria Chaparro et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.